目的 观察早期应用达格列净在急性心肌梗死（AMI）急诊经皮冠状动脉介入（PCI）术后患 者中的临床有效性及安全性。方法 选取 2020 年 9 月至 2021 年 9 月收治的 AMI 急诊 PCI 术后患者 68 例 作为研究对象。按随机数字表法分为研究组（34 例）和对照组（34 例）。两组患者急诊 PCI 术后均给予阿 司匹林、替格瑞洛等药物治疗。对照组给予美托洛尔、培哚普利等常规治疗，研究组在常规治疗基础上加 用达格列净，疗程 6 个月。比较两组患者 N 末端 B 型钠尿肽前体（NT⁃proBNP）、左心室射血分数（LVEF）、 左心室舒张末期容积（LVEDV）、左室收缩末期容积（LVESV）、心室重构率、心力衰竭发生率、再住院率及 不良反应发生情况等指标。结果 治疗 1、6 个月后，两组患者 NT⁃proBNP 水平较治疗前明显降低，LVEF 较治疗前明显提高（P < 0.05）。治疗 6 个月后，与对照组相比较，研究组 NT⁃proBNP、LVEDV、LVESV、心室重构及心力衰竭发生率明显降低（P < 0.05），且 LVEF 明显提高（P < 0.05）。但两组患者再住院率及药物 不良反应发生率均差异无统计学意义（P > 0.05）。结论 达格列净早期应用可有效减少 AMI 急诊 PCI 术 后患者心室重构，改善心功能，且安全性相对较好。 

Objective To investigate the clinical efficacy and safety of early application of Dapagliflozin in patients undergoing emergency percutaneous coronary intervention（PCI）after acute myocardial infarction（AMI）. Methods AMI patients undergoing emergency PCI（n = 68）were chosen from the Tengzhou Central People′s Hospital from September 2020 to September 2021，and divided randomly into control group（n = 34）and research group（n = 34）. Both groups of patients were given aspirin，ticagrelor，etc after PCI. The control group received conventional treatments such as metoprolol perindopril ，and the research group received dapagliflozin on bases of conventional oral medicine，a course for 6 months. The level of N ⁃terminal pro ⁃B ⁃type natriuretic peptide（NT ⁃ proBNP），left ventricular ejection fraction（LVEF），left ventricular end diastolic volume（LVEDV），left ventricular end systolic volume（LVESV），ventricular remodeling rate，the incidence of heart failure，the readmission rate， and incidence of adverse reactions were compared between the two groups. Results After 1 month and 6 months of treatment，the levels of NT⁃proBNP in the two groups were significantly lower than before treatment（P < 0.05）， and LVEF was significantly higher than before treatment（P < 0.05）. After 6 months of treatment，compared with control group，the levels of NT ⁃ proBNP、LVEDV、LVESV 、ventricular remodeling and Incidence of heart failure were significantly lower（P < 0.05），and LVEF was evidently higher in the study group（P < 0.05）. However，There were no significant differences in the rates of readmission and adverse drug reactions between the two groups（P > 0.05）. Conclusions Early application of dapagliflozin can effectively reduce ventricular remodeling and improve cardiac function in patients with acute myocardial infarction after emergency PCI，with relatively good safety.